Latest from Forbes: 

 

 

Assessment of ELN going forward!  Its on the positive side and I am sure one can find negative spins as well.  I chose to post because it does a good job of framing the arguments for the Alzheimers drug development and Tysabri safety situation to me and Greedy has stated his interest in learning how these tick.

 

Greedy has seen what the market does to bad drug news and now he should see the latter, more in depth analysis of the risk and actual potential and the ways this can go.

 

The science never matters when Wallstreet goes ballistic-generally overreacts.  Then the science takes over and stuff that happens is not always the drug companies fault.

 

Even this report does not expect gigantic moves back to where it was-its become more risky in general, but this company is not dead at all!  Far from it.

 

Enjoy!

 

kutz